New biomedical technologies are on the cusp of dramatically impacting not only healthcare and how we treat disease, but life itself. Visionary biologist, Andrew Hessel, spoke at our May What’s Now: San Francisco session exploring the extraordinary potential—and potential drawbacks—of gene editing and 3D printing in the field of biotech.
Related Resources
HFS’ view on Capgemini’s vision to deliver frictionless business operations
HFS’ perspective on the new era of business services
Webinar: Developing a multinational 5G/Edge strategy for the Intelligent Industry
Learn more about developing a multinational 5G/Edge strategy for the Intelligent Industry –...